check_circleStudy Completed
Cancer
Bayer Identifier:
20703
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
BAY2757556, no drug Larotrectinib related - OS
Trial purpose
The primary objective of the study is to evaluate overall survival for cancer patients with NTRK gene fusion and cancer patients without any NTRK gene mutations including gene fusion or other rearrangements under current standard of care.
Secondary objectives comprise the frequency of NTRK fusions, other NTRK re-arrangements, patient characteristics, treatment patterns, overall survival for patients with other NTRK gene rearrangements and overall survival after the start of antineoplastic therapy.
Secondary objectives comprise the frequency of NTRK fusions, other NTRK re-arrangements, patient characteristics, treatment patterns, overall survival for patients with other NTRK gene rearrangements and overall survival after the start of antineoplastic therapy.
Key Participants Requirements
Sex
AllAge
NaN - N/ATrial summary
Enrollment Goal
15971Trial Dates
March 2019 - September 2019Phase
N/ACould I Receive a placebo
N/AProducts
UnspecifiedAccepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many locations, United States |
Primary Outcome
- Overall survival - Index date 1 as the date of comprehensive genomic profiling (CGP) reportdate_rangeTime Frame:Data from January 2011 to July 2018
Trial design
Trial Type
ObservationalIntervention Type
N/ATrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A